|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�ر����� |
|
�ٴ����� |
| ��������������� | |
|
����� |
|
��ѧ�� |
| PubMed | |
|
Article by |
|
Article by |
�ر����ҵ��ٴ�Ӧ���о���չ
�����, ��ѧ��
����ҽ�ƴ�ѧ��һ����ҽԺƤ���Բ���, 230022
�ر�������һ����Ч�Ŀ����ҩ��,����ͷѢ������Ѣ�����Ѣ�����������dz����������нϺõ���Ч,������������,������Ӧ��,����IJ�����Ӧ��θ������Ӧ��Ƥ��,Ȼ�����ٴ�Ӧ�ù���������ע������ܷ������ټ������ز�����Ӧ,�糬����Ӧ�ۺ����ͼ��Ըλ���.�����ر���������������Ӧ��,�ٴ�����ʮ������,�����һ�����۾���.
[2] Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol,2001,39(1):91-95.
[3] Fuller LC, Smith CH, Cerio R, et al. A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol, 2001, 144(2):321-327.
[4] Filho ST, Cuce LC, Foss NT, et al. Efficacy, safety and tolerability of terbinafine for Tinea capitis in children;Brazilian multicentric study with daily oral tablets for 1,2 and 4 weeks. J Eur Acad Dermatol Venereol, 1998, 11(2):141-146.
[5] Koumantaki E, Kakourou T, Rallis E, et al. Doubled dose of oral terbinafine is required for Microsporum canis tinea capitis. Pediatr Dermatol, 2001, 18(4):339-342.
[6] Gupta AK, Adam P. Terbinafine pulse therapy is effective in tinea capitis. Pediatr Dermatol, 1998, 15(1):56-58.
[7] McClellan K J, Wiseman LR, Markham A. Terbinafine. An update of its use in superficial mycoses. Drugs, 1999, 58(1):179-202.
[8] Faergemann J, Jones JC, Hettler O, et al. Pityrosporum ovale(Malassezia furfur) as the causative agent of seborrhoeic dermatitis;new treatment options. Br J Dermatol, 1996, 134(Suppl 46):12-15.
[9] Lesher JL Jr. Oral therapy of common superficial fungal infections of the skin. J Am Acad Dermatol, 1999, 40(6 Pt 2):S31-S34.
[10] Tansch I, Decroix J, Gwiezdzinski Z, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol, 1998, 37(2):140-142.
[11] Pollak R, Billstein SA. Efficacy of terbinafine for toenail onychomycosis. A multicenter trial of various treatment durations. J Am Podiatr Med Assoc, 2001,91(3):127-131.
[12] Brautigam M, Nolting S, Schopf RE,et al. German randomized doubleblind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Br J Dermatol, 1996,134(Suppl 46):18-21.
[13] Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis;a new approach. J Dermatol,1996, 23(4):259-262.
[14] Segal R, Kritzman A, Cividalli L,et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol, 1996, 35(6):958.
[15] Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine,fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology,2001,202(3):235-238.
[16] De Cuyper C, Hindryckx PH. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol, 1999, 141(Suppl 56):15-20.
[17] Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis;North American multicenter trial. J Am Acad Dermatol, 1997, 37(5 Pt 1):740-745.
[18] Gharmoum MA, Elewski B. Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immunol, 1999, 6(6):921-923.
[19] Nagao K, Matsumoto H, Sugiura M, et al. A case of chromomycosis arising in a Japanese-Brazilian patient. Nippon Ishinkin Gakkai Zasshi,2001,42(3):119-122.
[20] Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs,1996,51(4):585-620.
[21] Roberts DT. Oral terbinafine(Lamisil) in the treatment of fungal infections of the skin and nails. Dermatology,1997,194(Suppl 1):37.
[22] Le Guyadec T, Saint-Blancard P, Bosonnet S, et al. Oral terbinafineinduced plantar pustular psoriasis. Ann Dermatol Venereol, 2000,127(3):279-281.
[23] Hall AP, Tate B. Acute generalized exanthematous pustulosis associated with oral terbinafine. Australas J Dermatol,2000,41(1):42-45.
[24] Bonsmann G, Schiller M, Luger TA, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol, 2001,44(6):925-931.
[25] Gupta AK, Porges AJ. Hypersensitivity syndrome reaction to oral terbinafine. Australas J Dermatol, 1998,39(3):171-172.
[26] Aguilar C, Mueller KK. Reversible agranulocytosis associated with oral terbinafine in a pediatric patient. J Am Acad Dermatol,2001,45(4):632-634.
[27] Garcia Rodriguez LA, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol, 1999,48(6):847-852.
[28] Gupta AK, del Rosso JQ, Lynde CW, et al. Hepatitis associated with terbinafine therapy;three case reports and a review of the literature.Clin Exp Dermatol, 1998, 3(2):64-67.